Quantum Computers Move From Theory to the Drug Discovery Pipeline

For all the money and ingenuity poured into modern pharmaceutical research, the odds of success remain stubbornly poor. Fewer than one in ten drug candidates that enter clinical trials ever wins regulatory approval, and the average cost of bringing a single approved medicine to market exceeds two billion dollars over a timeline stretching beyond a decade. A new theoretical review published in Frontiers in Drug Discovery argues that part of the problem lies deep inside the computational engines of drug design itself — and that quantum computing may offer a physically grounded way out of a bottleneck that has constrained the field for decades.

The review, led by Harshraj Gadbail and colleagues at Datta Meghe Institute of Higher Education and Research in India, maps quantum methods onto every stage of the drug discovery pipeline, from target identification through lead optimisation. Its central claim is carefully hedged but provocative: quantum processors could, in principle, break the accuracy–scalability trade-off that forces today’s computer-aided drug design (CADD) to sacrifice physical realism for computational speed. The authors are equally clear about what quantum computing cannot yet do, and their honest accounting of the gap between hype and hardware may be the most valuable part of the analysis.

The bottleneck they identify is rooted in the physics of molecular recognition. Classical CADD relies on molecular mechanics force fields — parametrised approximations that treat atoms as point charges connected by springs. These methods are fast enough to screen millions of compounds, but they deliberately ignore the quantum-mechanical phenomena that ultimately govern how drugs bind to their targets: polarisation, charge transfer, and electron correlation. Those effects matter most precisely where drugs matter most — at transition-metal active sites, in reactive covalent inhibitors, and in the charge-transfer interactions of enzyme pockets. Quantum-mechanical treatments can capture them, but on classical hardware their cost explodes. Coupled-cluster methods, the gold standard for reaction energetics, scale as O(N⁷) with system size, confining them to molecules of roughly 20 to 30 atoms — far smaller than any drug–protein complex.

Quantum computers attack this scaling problem at the hardware level. Where a classical bit must be either 0 or 1, a qubit can exist in a coherent superposition of both, and entangled qubits span a state space that grows exponentially with their number. A quantum processor can therefore encode a molecular wavefunction natively, in a way that would require exponentially many classical bits to represent explicitly. For targeted problem classes, quantum algorithms promise polynomial rather than exponential resource requirements for simulating electronic structure — the mathematical foundation of binding affinity, reactivity, and selectivity.

The reality, however, is that today’s devices belong to the NISQ era — Noisy Intermediate-Scale Quantum — with roughly 50 to 1,000 noisy qubits operating without full error correction. The workhorse algorithm of this era is the Variational Quantum Eigensolver, or VQE, a hybrid scheme in which a parameterised quantum circuit prepares a trial molecular wavefunction, the processor measures its energy, and a classical optimiser tunes the circuit parameters in an iterative loop. VQE is well suited to estimating ground-state energies, the quantities that underpin predictions of binding geometry and pharmacological activity. But the published demonstrations remain confined to toy systems — molecular hydrogen, lithium hydride, beryllium hydride — with active spaces of just 12 to 16 orbitals. No NISQ-based workflow has yet solved a chemically or industrially relevant problem, and the review is blunt on this point: VQE is a heuristic method whose convergence is not guaranteed, and its optimisation landscape suffers from exponentially flat “barren plateaus” that make training harder as systems grow.

To quantify the gap, the authors present a worked case study centred on CYP3A4, the iron-containing liver enzyme that metabolises roughly half of all marketed drugs. Its heme active site exhibits strong multireference electronic character that defeats classical methods. A faithful description requires an active space of about 50 electrons in 50 orbitals — a problem whose classical treatment would involve on the order of 10³⁰ determinants, utterly intractable. Encoding that Hamiltonian onto qubits demands roughly 100 to 200 logical qubits, which under surface-code error correction translates into millions of physical qubits. On today’s best hardware, such as IBM’s 127-qubit Eagle processor, a reduced 12-to-16-qubit VQE calculation is possible, but circuits of the required depth accumulate noise at current gate error rates near 10⁻³, and error-mitigation techniques like zero-noise extrapolation impose sampling overheads of 100- to 10,000-fold. Chemical accuracy — within one kilocalorie per mole — remains out of reach at full scale.

The review also situates quantum machine learning within the pipeline, and again tempers enthusiasm with evidence. Quantum-enhanced kernel methods and quantum support vector machines could, in principle, exploit high-dimensional genomic and multi-omics datasets where sample sizes are small relative to feature counts — a regime relevant to target prioritisation. But current benchmarks consistently show classical deep learning, particularly graph neural networks and transformers, outperforming demonstrated QML approaches on standard drug discovery tasks. The unresolved “quantum RAM” problem — efficiently loading large classical datasets onto a quantum processor — may offset any computational advantage, though streaming quantum algorithms under investigation at Google and collaborators offer a partial workaround whose applicability to molecular data is still unproven.

Industry interest is nonetheless real and growing. Boehringer Ingelheim has partnered with Google on quantum computing for drug discovery; Merck has worked with Zapata Computing on quantum simulation of protein–ligand interactions; Vertex Pharmaceuticals is exploring quantum methods for antibiotic design; and Biogen and Accenture Labs have investigated applications to neurological disease. Moderna and IBM have examined quantum approaches to mRNA vaccine design. The review notes, however, that quantitative performance claims from these collaborations rest on company statements rather than peer-reviewed benchmarks, and that independent verification of any quantum advantage over classical state-of-the-art methods has yet to appear.

Where might the first genuine wins come? The authors point to a crossover analysis by Goings and colleagues, who studied cytochrome P450 enzymes and estimated that quantum phase estimation becomes more beneficial than classical approaches at around 50 active orbitals — precisely the regime of drug-relevant metalloenzyme active sites. Beyond ground-state energies, emerging work on symmetry-adapted perturbation theory for non-covalent interactions, and on “quantum fingerprints” for predicting the reactivity of covalent warheads, suggests algorithms that go beyond simple total-energy calculations. The comparative framework in the review is sober: classical DFT handles small molecules at 1–3 kcal/mol accuracy but struggles beyond about 100 atoms; classical free-energy methods like FEP+ achieve roughly 1 kcal/mol for congeneric series but falter with metalloproteins and reactive inhibitors; fault-tolerant quantum phase estimation could match CCSD(T)-level accuracy for 50-plus-atom systems, but only after 2030 and only with millions of physical qubits.

The review closes with a realistic roadmap. Near-term progress will come from modular hybrid workflows, in which quantum subroutines handle specific electronic-structure bottlenecks inside otherwise classical pipelines — a strategy that preserves proven classical software while expanding the quantum component as hardware matures. The critical hardware hurdle is reducing physical qubit error rates from roughly 10⁻³ to the 10⁻⁶ level needed for practical surface-code error correction, while scaling qubit counts by three to four orders of magnitude. The field also lacks standardised benchmarks, reproducibility protocols, and regulatory frameworks: quantum measurements are stochastic and hardware-dependent, and agencies like the FDA and EMA will demand traceable, well-defined computational methods. Most quantum chemistry applications currently sit at technology readiness levels 2 to 3, with NISQ applications potentially reaching levels 4 to 5 within five to ten years. The authors’ conclusion reframes the technology’s promise in appropriately measured terms: quantum computing is not a disruptive replacement for classical drug design, but a foundation being laid to dissolve, eventually, the accuracy–scalability paradox that has long constrained it.

Subject of Research: Applications of quantum computing, including VQE and quantum machine learning, across the pharmaceutical drug discovery pipeline

Article Title: Quantum computing in drug discovery

Article References: Quantum computing in drug discovery. (n.d.). https://doi.org/10.3389/fddsv.2026.1815176

Image Credits: AI Generated

DOI: 10.3389/fddsv.2026.1815176

Keywords: quantum computing, drug discovery, VQE, quantum machine learning, CADD, NISQ, fault-tolerant quantum computing, CYP3A4, electronic structure, error correction, pharmaceutical industry, quantum chemistry